An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma
Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far met with limited success. A potential reason for this lack of...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2025-09-01
|
| Schriftenreihe: | Molecular Therapy: Oncology |
| Schlagworte: | |
| Online-Zugang: | http://www.sciencedirect.com/science/article/pii/S2950329925000992 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|